Effect and safety Of ticagrelor on platelet in ＞75 years old patients undergoing PCI
10.3969/j.issn.1009-0126.2018.03.003
- VernacularTitle:替格瑞洛对75岁以上冠状动脉介入治疗患者抗血小板疗效及安全性分析
- Author:
Lin CAI
1
;
Feng ZHANG
;
Yudong RONG
;
Jing ZHANG
;
Huizhen WANG
;
Wenmin JIN
;
Xiaofei WANG
Author Information
1. 300192,天津市第一中心医院老年病科
- Keywords:
platelet aggregation inhibitors;
aspirin;
acute coronary syndrome;
stents;
thrombosis
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2018;20(3):234-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect and safety of ticagrelor on platelet in ＞75 years old patients undergoing PCI.Methods One hundred and twenty ＞75 years old patients with acute coronary syndrome undergoing PCI were randomly divided into observation group treated with aspirin+ticagrelor (n =60) and control group treated with aspirin+ clopidogrel (n =60).They were followed up for 1 year after PCI.The major adverse cardiovascular events (MACE),bleeding events,drug-related side effects and all-cause mortality were compared between the two groups.Results No instent thrombosis occurred in any patients,myocardial infarction occurred in 2 patients,angina pectoris occurred in 5 patients and 3 patients died in observation group after 1 year of PCI.Instent thrombosis occurred in 4 patients,myocardial infarction occurred in 3 patients,angina pectoris occurred in 6 patients,and 4 patients died in control group after 1 year of PCI.The incidence of instent thrombosis was significantly lower while that of mild dyspnea was significantly higher in observation group than in control group (0％ vs 6.7％,10.0％ vs 0％,P＜0.05).Conclusion Ticagrelor can effectively prevent instent thrombosis and does not increase the risk of bleeding in ＞75 years old patients after PCI.
